• Explore /
  • Poster
  • / Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment.

Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment.

Abstract Poster

Authors

null

Thomas Hoehler

Department of Medicine I, Prosper Hospital Recklinghausen, Recklinghausen, Germany

Thomas Hoehler , Thomas Decker , Christoph Schimanski , Stephan H. Schmitz , Stephan Kanzler , Jacqueline Rauh , Ursula Vehling-Kaiser , Helga Bernhard , Thomas Hoffmann , Norbert Niederle , Ulla Von Verschuer , Goetz von Wichert , Thomas Wagner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

2008-000803-26

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3586)

DOI

10.1200/jco.2013.31.15_suppl.3586

Abstract #

3586

Poster Bd #

7D

Abstract Disclosures

Similar Posters

First Author: J. Randolph Hecht

First Author: Benoist Chibaudel

First Author: Axel Grothey

First Author: Marc Van Den Eynde